Concepedia

Xuetong Liu

XL

Statistics

Publications

2

Citations

588

H-Index

2

Active since

2013

Affiliations

Harbin Medical University(Current)

Peking University Cancer Hospital

Beijing Chest Hospital

Sun Yat-sen University Cancer Center

Shanghai Pulmonary Hospital

Xuetong Liu is an author at Harbin Medical University specializing in pharmacology, erlotinib therapy, and oncology.

Publications per year

2013–2015

2

Publications

2

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 468 citations

, , +14

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

, , +14

1–2 of 2